Two years of Phase 1/2 momentum collapsed in a single readout: Ultragenyx’s Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed both its primary endpoint and its key secondary endpoint, announced September 2, 2026. The trial did not achieve the primary measure of change from baseline in Bayley-4 cognitive raw score, and net response on the Multidomain Responder Index (MDRI) also came up empty, with no differences between treated and control groups that could support efficacy across any of the MDRI’s five individual domains, including cognition and receptive communication.
The miss is particularly sharp given how convincingly the earlier-stage data read. In April 2024, interim Phase 1/2 results showed rapid and clinically significant improvement in cognition on Bayley-4 relative to natural history data, alongside behavioral gains. That signal was strong enough to justify a pivotal program. The Phase 3 failure does not mean the earlier data were wrong, but it does illustrate how profoundly Angelman syndrome resists the translation from open-label, smaller cohorts to randomized, controlled trials, a pattern the field has confronted repeatedly. The safety profile in Aspire was consistent with Phase 1/2, so the drug did not become dangerous; it simply did not work by the standards a registrational study demands.
For Ultragenyx, the strategic consequences are real. Apazunersen was one of the company’s highest-profile rare neurology bets, and Angelman syndrome is a condition where families have waited a very long time for disease-modifying options. The failure also puts pressure on how the field thinks about endpoint selection for neurodevelopmental disorders. The MDRI was designed to capture broad functional benefit across five domains simultaneously, and the fact that none of those five domains individually separated from control is not a measurement artifact. It suggests the drug did not move the needle on function at the doses and duration studied.
The single marker to track now is whether Ultragenyx pursues any exploratory subgroup analyses that might identify a responsive population, or whether the program is formally discontinued. That decision will arrive with the full data presentation, and it will determine whether apazunersen has any remaining clinical future.
What the announcement doesn’t say
The 8-K does not disclose the full trial design, including the number of patients enrolled, the duration of treatment, or the dose levels studied in Aspire. The release does not say whether Ultragenyx intends to present the complete dataset at an upcoming scientific conference or submit it for peer review, leaving the research community without granular detail on the five MDRI domains or any subgroup performance. The release does not disclose what, if any, exploratory or pre-specified secondary endpoints showed directional signal, nor whether a biomarker or pharmacodynamic readout confirmed target engagement in the Phase 3 population. The release does not address next steps for the apazunersen program, including whether a redesigned trial, a different patient population, or program discontinuation is under consideration. We would welcome a full data package or pipeline update from Ultragenyx, and will update this piece if those details become available.
Source link: https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/rare-20260902.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
